8.78

5.17% -0.51

Vanda Pharmaceuticals Inc (VNDA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.29

Offen:

$9.23

24-Stunden-Volumen:

881.02K

Relative Volume:

0.33

Marktkapitalisierung:

$518.38M

Einnahmen:

$192.64M

Nettoeinkommen (Verlust:

$2.51M

KGV:

167.56

EPS:

0.0524

Netto-Cashflow:

$12.42M

1W Leistung:

+11.66%

1M Leistung:

+44.66%

6M Leistung:

+95.34%

1J Leistung:

+79.07%

1-Tages-Spanne:

$8.68

$9.42

1-Wochen-Bereich:

$7.70

$9.94

52-Wochen-Spanne:

$3.8092

$9.94

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Firmenname

Vanda Pharmaceuticals Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

202-734-3400

Adresse

2200 PENNSYLVANIA AVE NW, WASHINGTON

Mitarbeiter

533

Twitter

Nächster Verdiensttermin

2025-05-02

Neueste SEC-Einreichungen

VNDA's Discussions on Twitter

Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VNDA Vanda Pharmaceuticals Inc	8.77	549.11M	192.64M	2.51M	12.42M	0.0524
VRTX Vertex Pharmaceuticals Inc	473.52	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	746.24	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	705.10	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	312.69	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.42	31.65B	5.36B	287.73M	924.18M	2.5229

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-05	Eingeleitet	Truist	Buy
2025-11-05	Eingeleitet	B. Riley Securities	Buy
2024-10-31	Eingeleitet	H.C. Wainwright	Buy
2024-07-11	Eingeleitet	Cantor Fitzgerald	Overweight
2022-02-25	Herabstufung	Jefferies	Buy → Hold
2021-05-12	Eingeleitet	BofA Securities	Buy
2021-01-14	Herabstufung	Citigroup	Buy → Neutral
2020-10-29	Hochstufung	Citigroup	Neutral → Buy
2020-06-09	Herabstufung	Citigroup	Buy → Neutral
2020-03-16	Herabstufung	Oppenheimer	Perform → Underperform
2020-03-12	Hochstufung	Citigroup	Neutral → Buy
2019-11-07	Herabstufung	Citigroup	Buy → Neutral
2019-08-01	Hochstufung	Citigroup	Neutral → Buy
2019-07-25	Herabstufung	Stifel	Buy → Hold
2018-12-11	Herabstufung	Oppenheimer	Outperform → Perform
2018-12-04	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2018-12-04	Bestätigt	Jefferies	Buy
2018-11-08	Fortgesetzt	Jefferies	Buy
2018-09-21	Fortgesetzt	Oppenheimer	Outperform
2018-05-23	Eingeleitet	Citigroup	Buy
2018-01-19	Eingeleitet	Seaport Global Securities	Buy
2017-09-14	Bestätigt	Piper Jaffray	Overweight
2017-06-27	Fortgesetzt	Piper Jaffray	Overweight
2017-05-26	Eingeleitet	H.C. Wainwright	Buy
2017-04-12	Eingeleitet	Oppenheimer	Outperform
2016-11-09	Eingeleitet	Aegis Capital	Buy
2016-10-06	Fortgesetzt	Jefferies	Buy

Alle ansehen

Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten

01:17 AM

Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN

01:17 AM

Mar 12, 2026

DC Circ. Spends Hours Debating 'Same' Generic Label Reqs - Law360

Mar 12, 2026

Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87% - Markets Mojo

Mar 12, 2026

Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com Nigeria

Mar 12, 2026

Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st

Mar 12, 2026

Mar 11, 2026

Vanda Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com Canada

Mar 11, 2026

VNDA: BYSANTI and Nereus launches drive growth, with key pipeline milestones expected by year-end - TradingView

Mar 11, 2026

Mar 10, 2026

Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy - TipRanks

Mar 10, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA) Sets New 52-Week HighWhat's Next? - MarketBeat

Mar 10, 2026

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits

Mar 05, 2026

Truist Financial Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Mar 05, 2026

Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline By Investing.com - Investing.com Australia

Mar 05, 2026

Truist Securities Initiates Coverage on Vanda Pharmaceuticals (V - GuruFocus

Mar 05, 2026

Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target - marketscreener.com

Mar 05, 2026

Mar 04, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares - MarketBeat

Mar 04, 2026

Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat

Mar 04, 2026

Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells 42,434 Shares of Stock - MarketBeat

Mar 04, 2026

Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat

Mar 04, 2026

Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock - MarketBeat

Mar 04, 2026

Vanda Pharmaceuticals (VNDA) SVP sells 42,431 shares to cover RSU tax - Stock Titan

Mar 04, 2026

VNDA SEC FilingsVanda Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 04, 2026

Q1 Earnings Estimate for VNDA Issued By HC Wainwright - MarketBeat

Mar 04, 2026

VNDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

After years of dispute with FDA, Vanda will get a public hearing for jet lag drug - Endpoints News

Mar 04, 2026

Mar 03, 2026

FDA Grants Rare Hearing for Vanda Pharmaceuticals' (VNDA) Jet La - GuruFocus

Mar 03, 2026

Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits

Mar 03, 2026

Vanda secures win in regulatory showdown as FDA agrees to review jet lag drug - The Business Journals

Mar 03, 2026

Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years - marketscreener.com

Mar 03, 2026

Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag - marketscreener.com

Mar 03, 2026

Vanda Pharmaceuticals (VNDA) Secures Rare FDA Hearing for Hetlio - GuruFocus

Mar 03, 2026

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Finviz

Mar 03, 2026

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - ChartMill

Mar 03, 2026

FDA grants first drug approval hearing in 40 years over jet lag pill - Stock Titan

Mar 03, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat

Mar 03, 2026

Mar 02, 2026

[144] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan

Mar 02, 2026

Feb 28, 2026

Document - SEC.gov

Feb 28, 2026

Feb 27, 2026

EMA Turns Down Vanda’s Iloperidone And Acadia’s Daybu, Backs 12 Others For EU Approval - Citeline News & Insights

Feb 27, 2026

Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone - marketscreener.com

Feb 27, 2026

Feb 26, 2026

Vanda Pharmaceuticals Announces Participation in the 2026 Citize - GuruFocus

Feb 26, 2026

Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference - Intellectia AI

Feb 26, 2026

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - ChartMill

Feb 26, 2026

A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st

Feb 26, 2026

Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley - Yahoo Finance

Feb 26, 2026